Collectively, the sustained CIP2A-mediated inhibition of PP2A promotes a number of signalling pathways that progress the pathogenesis of LC (as described above), and suggests therapeutically targeting CIP2A/PP2A in LC will have merit. The gene discussed is PTPA; the disease is laryngotracheoesophageal cleft.